Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâ€™s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâ€™s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Copenhagen			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

30/05/24	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/06/22	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Market Cap	10.46B 69.79B 9.34B 8.63B 7.82B 14.62B 993B 14.87B 104B 41.09B 520B 39.24B 38.41B 1,640B	P/E 2017	-154x	P/E 2018	-708x
Enterprise Value	10.49B 69.99B 9.36B 8.65B 7.84B 14.67B 995B 14.91B 104B 41.21B 522B 39.35B 38.51B 1,644B	EV / Sales 2017	49.4x	EV / Sales 2018	95.8x
Free-Float	10%	Yield 2017 *	-	Yield 2018	-

30/05/24	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/06/22	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI
26/04/21	Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	CI
17/02/20	Veloxis Pharmaceuticals A/S Announces Board Appointments	CI
07/02/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	CI
30/01/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
30/01/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
14/01/20	Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	CI
25/11/19	Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
25/11/19	Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	CI
13/11/19	Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
12/11/19	Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
31/10/19	Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	CI

02/06/21	Scandion Oncology A/S : appoints Johnny Stilou as new CFO	AQ
17/02/20	Veloxis Pharmaceuticals A/S : Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020	AQ
29/01/20	Veloxis Pharmaceuticals A/S : Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S	AQ
27/01/20	Veloxis Pharmaceuticals A/S : Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S	AQ
27/01/20	Veloxis Pharmaceuticals A/S : - Major Shareholder Notifications	AQ

Veloxis Pharmaceuticals A/S Stock

Stocks

VELO

DK0060048148

Pharmaceuticals

Valuation: Veloxis Pharmaceuticals A/S

Latest news: Veloxis Pharmaceuticals A/S

Press Releases: Veloxis Pharmaceuticals A/S

News in other languages: Veloxis Pharmaceuticals A/S

Managers and Directors: Veloxis Pharmaceuticals A/S

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Daisuke Matsuo CEO	Chief Executive Officer	-	-
Ulf Meier-Kriesche CTO	Chief Tech/Sci/R&D Officer	-	13/09/2017
Stacy Wheeler COO	Chief Operating Officer	-	01/03/2016

Director	Title	Age	Since
Keigo Nakatsukasa CHM	Chairman	-	-
Yusuke Hiramatsu BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
ELI LILLY AND COMPANY	-2.54%	+1.31%	+55.10%	+120.84%	1,135B
JOHNSON & JOHNSON	-1.42%	+3.23%	+37.07%	+74.26%	636B
ABBVIE INC.	+0.16%	+0.08%	+25.14%	+97.36%	505B
ROCHE HOLDING AG	-0.31%	+3.09%	+43.92%	+64.55%	378B
MERCK & CO., INC.	-1.34%	-0.47%	+66.63%	+40.56%	358B
NOVARTIS AG	-0.68%	+2.65%	+22.46%	+51.48%	295B
ASTRAZENECA PLC	-1.20%	+3.04%	+2.62%	+26.97%	266B
AMGEN INC.	-1.79%	+1.57%	+49.97%	+60.87%	237B
GILEAD SCIENCES, INC.	-0.73%	-0.10%	+29.24%	+101.19%	193B
Average	-0.60%	+1.95%	+36.91%	+70.90%	400.6B
Weighted average by Cap.	-0.26%	+2.66%	+40.99%	+82.13%

	2017	2018
Net sales	30.17M 201M 26.94M 24.89M 22.55M 42.19M 2.86B 42.89M 299M 119M 1.5B 113M 111M 4.73B	39.49M 264M 35.27M 32.58M 29.53M 55.24M 3.75B 56.15M 392M 155M 1.96B 148M 145M 6.19B
Net income	-9.54M -63.69M -8.52M -7.87M -7.13M -13.35M -906M -13.57M -94.73M -37.5M -475M -35.81M -35.05M -1.5B	-5.28M -35.28M -4.72M -4.36M -3.95M -7.39M -502M -7.51M -52.47M -20.77M -263M -19.83M -19.41M -829M
Net Debt	18.05M 120M 16.12M 14.89M 13.5M 25.25M 1.71B 25.67M 179M 70.95M 898M 67.75M 66.31M 2.83B	29.38M 196M 26.24M 24.24M 21.97M 41.1M 2.79B 41.78M 292M 115M 1.46B 110M 108M 4.61B